Mason Alexander’s Post

📊 A new issue of our monthly “𝗙𝗖𝗙 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 & 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗠𝗼𝗻𝗶𝘁𝗼𝗿 – 𝗘𝘂𝗿𝗼𝗽𝗲” is now available. 🔍 Read the latest financing trends in venture capital in the European life science industry. Our monitor covers Biotech, Pharmaceutical, MedTech, and HealthTech companies. As of the end of December 2023 we identify the following current VC trends in Europe: - In 2023, overall Life Sciences funding has reached EUR 8,949m - Biotech received 42% of the total investment volume (+1% compared to the previous month) - Oncology dominates as the top indication in Biotech - Freya BioSciences (Denmark) has the highest transaction volume of EUR 35m in December, followed by Laza Medical (Switzerland) EUR 33m and Eligo Bioscience (France) EUR 30m - The European Innovation Council and SMEs Executive Agency (EISMEA) (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by JEITO (France) and Forbion (Netherlands) - Top 5 Deals exceed EUR 130m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom) More here: https://lnkd.in/dDUbKnsD #VentureCapital #LifeSciences #Biotech #Pharma #MedTech #HealthTech #InvestmentTrends #Europe #FCFMonitor #HealthcareInvestment #fcffoxcorporatefinance #financingspecialist #corporatefinance #investmentbanking #capitalmarkets

Our new Healthcare & Life Sciences Venture Capital Monitor Europe is now online. Investment volumes did pick up in the second half of 2023 in Europe setting us up positively for 2024

📊 A new issue of our monthly “𝗙𝗖𝗙 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 & 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗠𝗼𝗻𝗶𝘁𝗼𝗿 – 𝗘𝘂𝗿𝗼𝗽𝗲” is now available. 🔍 Read the latest financing trends in venture capital in the European life science industry. Our monitor covers Biotech, Pharmaceutical, MedTech, and HealthTech companies. As of the end of December 2023 we identify the following current VC trends in Europe: - In 2023, overall Life Sciences funding has reached EUR 8,949m - Biotech received 42% of the total investment volume (+1% compared to the previous month) - Oncology dominates as the top indication in Biotech - Freya BioSciences (Denmark) has the highest transaction volume of EUR 35m in December, followed by Laza Medical (Switzerland) EUR 33m and Eligo Bioscience (France) EUR 30m - The European Innovation Council and SMEs Executive Agency (EISMEA) (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by JEITO (France) and Forbion (Netherlands) - Top 5 Deals exceed EUR 130m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom) More here: https://lnkd.in/dDUbKnsD #VentureCapital #LifeSciences #Biotech #Pharma #MedTech #HealthTech #InvestmentTrends #Europe #FCFMonitor #HealthcareInvestment #fcffoxcorporatefinance #financingspecialist #corporatefinance #investmentbanking #capitalmarkets

📊 A new issue of our monthly “𝗙𝗖𝗙 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 & 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗠𝗼𝗻𝗶𝘁𝗼𝗿 – 𝗘𝘂𝗿𝗼𝗽𝗲” is now available. 🔍 Read the latest financing trends in venture capital in the European life science industry. Our monitor covers Biotech, Pharmaceutical, MedTech, and HealthTech companies. As of the end of October 2023, we identify the following current VC trends in Europe: - In 2023, overall Life Sciences funding has reached EUR 7,324m - Biotech received 42% of the total investment volume (-3% compared to the previous month) - Oncology dominates as the top indication in Biotech - Agomab Therapeutics (Belgium) has the highest transaction volume of EUR 94m in October, followed by Minervax ApS (Denmark) EUR 54m and AstronauTx (United Kingdom) EUR 54m - The European Innovation Council and SMEs Executive Agency (EISMEA) (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by Revival Healthcare Capital (United States) and Gilde Healthcare Partners (Netherlands) - Top 5 Deals exceed EUR 130m each, the largest transaction amounted to EUR 683m in YgEia3 (United Kingdom) More here: https://lnkd.in/d57pvYgw #VentureCapital #LifeSciences #Biotech #Pharma #MedTech #HealthTech #InvestmentTrends #Europe #FCFMonitor #HealthcareInvestment #fcffoxcorporatefinance #financingspecialist #corporatefinance #investmentbanking #capitalmarkets

Interesting Fact of the Day: The Funding Dilemma in European Pharma 🤔💡 Did you know? When it comes to raising funds, European pharma startups face a significant challenge (see our previous analysis). On average, Series A rounds in Europe secure only $11M, in sharp contrast to the global average of $32M. Meanwhile, advancing a drug to phase 1 clinical trials typically costs around $53M. Why This Matters: This funding gap could be slowing down the pace of pharmaceutical innovation in Europe, delaying promising treatments from reaching those in need. What's Being Done: The First Capital for Cures Summit aims to tackle this issue head-on, exploring ways to boost funding for European pharma startups. https://lnkd.in/egePvu-R Stay Informed, Stay Engaged: This summit represents a crucial step toward bridging the funding divide and accelerating the journey from lab to patient. #PharmaFacts #FundingGap #CapitalForCures #EuropeanInnovation

Don't miss Neel Desai, Executive Director of Business Development & Licensing at Biogen, speaking on the Partnering with Pharma panel at RESI Boston on September 25 at the Westin Copley Hotel. Neel brings valuable insights into how big pharma evaluates and sources innovative therapeutics. Learn about Biogen's areas of interest, evaluation process, and advice for startups looking to partner with pharma companies. Join us to hear from Neel and other industry experts on: • How pharma sources assets • Key factors in evaluations • Emerging trends in therapeutics • Opportunities for early-stage companies Don't miss this chance to gain insider knowledge on pharma partnering strategies! Register: https://lnkd.in/eKaf4xPb #RESIBoston #BiopharmaPartnering #DrugDiscovery

📊 A new issue of our monthly “𝗙𝗖𝗙 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 & 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗠𝗼𝗻𝗶𝘁𝗼𝗿 – 𝗘𝘂𝗿𝗼𝗽𝗲” is now available. 🔍 Read the latest financing trends in venture capital in the European life science industry. Our monitor covers Biotech, Pharmaceutical, MedTech, and HealthTech companies. As of the end of November 2023 we identify the following current VC trends in Europe: - In 2023, overall Life Sciences funding has reached EUR 8,390m - Biotech received 41% of the total investment volume (-1% compared to the previous month) - Oncology dominates as the top indication in Biotech - VectorY Therapeutics (Netherlands) has the highest transaction volume of EUR 129m in November, followed by EyeBio (United Kingdom) EUR 122m and NMD Pharma A/S (Denmark) EUR 75m - The European Innovation Council and SMEs Executive Agency (EISMEA) (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by Forbion (Netherlands) and JEITO (France) - Top 5 Deals exceed EUR 130m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom) More here: https://lnkd.in/desdBhEi #VentureCapital #LifeSciences #Biotech #Pharma #MedTech #HealthTech #InvestmentTrends #Europe #FCFMonitor #HealthcareInvestment #fcffoxcorporatefinance #financingspecialist #corporatefinance #investmentbanking #capitalmarkets

📊 A new issue of our monthly “𝗙𝗖𝗙 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 & 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗠𝗼𝗻𝗶𝘁𝗼𝗿 – 𝗘𝘂𝗿𝗼𝗽𝗲” is now available. 🔍 Read the latest financing trends in venture capital in the European life science industry. Our monitor covers Biotech, Pharmaceutical, MedTech, and HealthTech companies. As of the end of October 2023, we identify the following current VC trends in Europe: - In 2023, overall Life Sciences funding has reached EUR 7,324m - Biotech received 42% of the total investment volume (-3% compared to the previous month) - Oncology dominates as the top indication in Biotech - Agomab Therapeutics (Belgium) has the highest transaction volume of EUR 94m in October, followed by Minervax ApS (Denmark) EUR 54m and AstronauTx (United Kingdom) EUR 54m - The European Innovation Council and SMEs Executive Agency (EISMEA) (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by Revival Healthcare Capital (United States) and Gilde Healthcare (Netherlands) - Top 5 Deals exceed EUR 130m each, the largest transaction amounted to EUR 683m in YgEia3 (United Kingdom) More here: https://lnkd.in/d57pvYgw #VentureCapital #LifeSciences #Biotech #Pharma #MedTech #HealthTech #InvestmentTrends #Europe #FCFMonitor #HealthcareInvestment #fcffoxcorporatefinance #financingspecialist #corporatefinance #investmentbanking #capitalmarkets

🔬 Industry Insight: Radiopharmaceuticals Emerge as a Key Area for Investment and M&A At YOBE Ventures, we're always tracking the latest trends in investment opportunities. Recently, radiopharmaceuticals have caught our attention as a rapidly growing sector in the pharmaceutical industry. Key Developments: 1. Funding: Isotope Technologies Munich secured over $200 million in an equity round led by Temasek Holdings. 2. M&A Activity: AstraZeneca completed a $2.1 billion acquisition of Fusion Pharmaceuticals. 3. Startup Ecosystem: At least 12 private companies focused on radiopharmaceuticals have raised venture or growth funding in the past two years, totaling nearly $1.3 billion. 4. Clinical Promise: Treatments are showing potential for addressing some of humanity's most intractable diseases. This surge in investment aligns with our commitment to backing innovative companies that solve real-world problems. The radiopharmaceuticals sector combines cutting-edge science with significant market potential, making it an area ripe for smart investments. What are your thoughts on the future of radiopharmaceuticals? How do you see this impacting the broader healthcare and investment landscapes? #InvestmentTrends #Radiopharmaceuticals #VentureCapital #HealthcareInnovation #YOBEVentures

The Pharma M&A landscape has shifted towards smaller and earlier stage Biotech deals. This presents an exciting opportunity for Pharma to tackle more complex disease areas and accelerate access to new technologies and treatments. However, Biotech deals come with many challenges, with a greater ratio of clinical to commercial assets, leaner infrastructure and innovative therapies with new delivery pathways. In this article, we provide an overview of the challenges that these deals present, and how Pharma can proactively overcome these hurdles to realise the full value. Click here to find out more and reach out to us if you like to discuss further: https://lnkd.in/gtry8F6R Christian K. Moldt Suzanne Ellis Sky Milch Thalita Marinho Johnathon Marshall André Sassmannshausen Tom Southwell Jess Abel Eleanor Craggs Katja Haug